Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The high molecular weight, multidomain VAR2CSA protein mediating adhesion of Plasmodium falciparum-infected erythrocytes in the placenta is the leading candidate for a pregnancy malaria vaccine. However, it has been difficult so far to generate strong and consistent adhesion blocking antibody responses against most single-domain VAR2CSA immunogens. Recent advances in expression of the full-length recombinant protein showed it binds with much greater specificity and affinity to chondroitin sulphate A (CSA) than individual VAR2CSA domains. This raises the possibility that a specific CSA binding pocket(s) is formed in the full length antigen and could be an important target for vaccine development. In this study, we compared the immunogenicity of a full-length VAR2CSA recombinant protein containing all six Duffy binding-like (DBL) domains to that of a three-domain construct (DBL4-6) in mice and rabbits. Animals immunized with either immunogen acquired antibodies reacting with several VAR2CSA individual domains by ELISA, but antibody responses against the highly conserved DBL4 domain were weaker in animals immunized with full-length DBL1-6 recombinant protein compared to DBL4-6 recombinant protein. Both immunogens induced cross-reactive antibodies to several heterologous CSA-binding parasite lines expressing different VAR2CSA orthologues. However, antibodies that inhibited adhesion of parasites to CSA were only elicited in rabbits immunized with full-length immunogen and inhibition was restricted to the homologous CSA-binding parasite. These findings demonstrate that partial and full-length VAR2CSA immunogens induce cross-reactive antibodies, but inhibitory antibody responses to full-length immunogen were highly allele-specific and variable between animal species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably antibodies to the full length VAR2CSA inhibited the binding of homologous parasite isolate [23,58] but not heterologous parasites [56,58].”
From Designing a VAR2CSA-based vaccine to prevent placental malaria (2015) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Su, X.-Z., Heatwole, V. M., Wertheimer, S. P., Guinet, F., Herrfeldt, J. A., Peterson, D. S., Ravetch, J. A., & Wellems, T. E. (1995) · Cell · doi:10.1016/0092-8674(95)90055-1 · Cited by 1,219
Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta
Fried, M., & Duffy, P. E. (1996) · Science · doi:10.1126/science.272.5267.1502 · Cited by 1,108 · cited 1×
“A key feature of PAM is the selective accumulation of Plasmodium falciparum infected erythrocytes (IEs) in the placenta mediated by adhesion to chondroitin sulfate A (CSA) [2].”
BackgroundBaruch, D. I., Pasloske, B. L., Singh, H. B., Bi, X., Ma, X. C., Feldman, M., Taraschi, T. F., & Howard, R. J. (1995) · Cell · doi:10.1016/0092-8674(95)90054-3 · Cited by 1,030 · cited 1×
“VAR2CSA belongs to the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family encoded by var genes [8–10] and is the leading PAM vaccine candidate [11–17].”
BackgroundSmith, J. D., Chitnis, C. E., Craig, A. G., Roberts, D. J., Hudson-Taylor, D. E., Peterson, D. S., Pinches, R., Newbold, C. I., & Miller, L. H. (1995) · Cell · doi:10.1016/0092-8674(95)90056-x · Cited by 1,005 · cited 1×
“VAR2CSA belongs to the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family encoded by var genes [8–10] and is the leading PAM vaccine candidate [11–17].”
BackgroundSelf-citationSalanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702
Maternal antibodies block malaria
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998) · Nature · doi:10.1038/27570 · Cited by 659 · cited 1×
“Although women exposed to placental infections acquire antibodies that block adhesion of geographically diverse placental isolates [5], the specific targets of inhibitory antibodies remain unknown and inhibitory epitopes appear to be at least partially strain-dependent [30–32].”
BackgroundScherf, A., Hernandez-Rivas, R., Buffet, P., Bottius, E., Benatar, C., Pouvelle, B., Gysin, J., & Lanzer, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5418 · Cited by 610 · cited 1×
“FCR3csa [46], 7G8csa [23], HB3csa allele A and HB3csa allele B [24], 3D7/NF54csa [31], Pf2004csa [24,27] and Pf2006csa [24,27] were maintained by periodic selection on CSA.”
BackgroundEvidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041579 · Cited by 604 · cited 1×
“Furthermore, VAR2CSA appears to be a major target of the antibody mediated immune response in pregnant women [15,20], and parasites in which var2csa is genetically disrupted largely lose the ability to bind to CSA [12,17] and placental syncytiotrophoblast [21], suggesting it is the primary var gene responsible for pla…”
BackgroundSnounou, G., Zhu, X., Siripoon, N., Jarra, W., Thaithong, S., Brown, K. N., & Viriyakosol, S. (1999) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(99)90120-7 · Cited by 546 · cited 1×
“Parasite genotyping was done with MSP1/MSP2 primers [47].”
MethodThe Sick Placenta—The Role of Malaria
Brabin, B. J., Romagosa, C., Abdelgalil, S., Menéndez, C., Verhoeff, F. H., McGready, R., Fletcher, K. A., Owens, S., d'Alessandro, U., Nosten, F., et al. (2004) · Placenta · doi:10.1016/j.placenta.2003.10.019 · Cited by 375 · cited 1×
“Pregnancy associated malaria (PAM) is a major cause of poor mother/child health and increases the risk for maternal anemia, prematurity, low birth weight and infant morbidity and mortality [1].”
Background
Cited by
Chan, J.-A., Fowkes, F. J. I., & Beeson, J. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1614-3 · Cited by 168
“Furthermore, antibodies generated against full-length [160, 281] and single domains of vAR2CSA [282] by immunisation inhibited adhesion of Ies to CSA, suggesting that vaccine-induced antibodies may have a protective function in vivo.”
BackgroundSelf-citationClausen, T. M., Christoffersen, S., Dahlbäck, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbæk, M. Ø., Andersen, D., Berisha, B., Ditlev, S. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348839 · Cited by 173
“Although recombinant full-length VAR2CSA is very immunogenic the antibodies produced are not crossinhibitory (43).”
BackgroundSirima, S. B., Richert, L., Chêne, A., Konate, A. T., Campion, C., Dechavanne, S., Semblat, J.-P., Benhamouda, N., Bahuaud, M., Loulergue, P., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30739-x · Cited by 124
Self-citationA Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection
Zanghì, G., Vembar, S. S., Baumgarten, S., Ding, S. D., Guizetti, J., Bryant, J. M., Mattei, D., Jensen, A. T. R., Rénia, L., Goh, Y. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.075 · Cited by 118
“…were blocked with 4% BSA in PBS for 30 min at RT and then incubated with primary antibody for 1 hr at RT; dilutions were 1:1,000 for anti-ATS, 1:1,000 for antiNF54_SpzPfEMP1, 1:200 for anti-var2CSA (Avril et al., 2011), and 1:15,000 for anti-CSP (Okitsu et al., 2007) antibodies in 3% BSA in PBS.”
MethodDesigning a VAR2CSA-based vaccine to prevent placental malaria
Fried, M., & Duffy, P. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.011 · Cited by 86
Var2CSA minimal CSA binding region is located within the N-terminal region
Srivastava, A., Gangnard, S., Dechavanne, S., Amirat, F., Lewit Bentley, A., Bentley, G. A., & Gamain, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020270 · Cited by 76
“Recently, we showed that immunization of rabbits with fulllength var2CSA generated inhibitory antibodies capable of blocking var2CSA and PEs adhesion to CSA [42].”
BackgroundSelf-citationBigey, P., Gnidehou, S., Doritchamou, J., Quiviger, M., Viwami, F., Couturier, A., Salanti, A., Nielsen, M. A., Scherman, D., Deloron, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir499 · Cited by 63
“Nevertheless, a recent work reports that immunization with full-length VAR2CSA did not induce potent cross-inhibitory antibodies [26].”
BackgroundProgress and Insights Toward an Effective Placental Malaria Vaccine
Gamain, B., Chêne, A., Viebig, N. K., Ndam, N. T., & Nielsen, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634508 · Cited by 46
“Although antibodies raised against the full-length VAR2CSA may not be cross-inhibitory (76), several studies performed in rodents have shown that shorter constructs including the Nterminal region of VAR2CSA are able to induce cross-inhibitory antibodies preventing IEs from binding to CSA (77–81).”
BackgroundSelf-citationBordbar, B., Ndam, N. T., Bigey, P., Doritchamou, J., Scherman, D., & Deloron, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.065 · Cited by 43
Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria
Fried, M., Avril, M., Chaturvedi, R., Fernandez, P., Lograsso, J., Narum, D., Nielsen, M. A., Oleinikov, A. V., Resende, M., Salanti, A., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01106-12 · Cited by 38
“Immunization with recombinant full-length VAR2CSA protein induces antibodies that inhibit the binding of homologous parasites to a high degree (17, 18).”
BackgroundSelf-citationThe case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malaria
Hviid, L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.113 · Cited by 34
Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC
Chêne, A., Gangnard, S., Guadall, A., Ginisty, H., Leroy, O. Y., Havelange, N., Viebig, N. K., & Gamain, B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.010 · Cited by 36
“The potency study aiming to assess the stability of PRIMVAC over-time was performed in mice, a rodent species in which sufficient historical data exist to ensure that an immune response is developed [28].”
BackgroundSelf-citationPre-clinical and clinical development of the first placental malaria vaccine
Pehrson, C., Salanti, A., Theander, T. G., & Nielsen, M. A. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322512 · Cited by 34
“Although one study suggested that antibodies raised against VAR2CSA are not crossinhibitory [74], several studies have showed constructs from”
BackgroundBryant, J. M., Regnault, C., Scheidig‐Benatar, C., Baumgarten, S., Guizetti, J., & Scherf, A. (2017) · mBio · doi:10.1128/mbio.00729-17 · Cited by 31
“PfEMP1 proteins were detected with guinea pig anti-PfEMP1 acidic transmembrane segment (ATS) (46) and rabbit anti-VAR2CSA PfEMP1 (47) primary antibodies, followed by goat anti-guinea pig horseradish peroxidase (HRP) (Abcam, Inc.”
BackgroundDeveloping vaccines to prevent malaria in pregnant women
Ndam, N. T., & Deloron, P. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1049595 · Cited by 30
“However, in addition to the technological difficulties of producing such a large protein in a vaccine perspective, some observations described low potential for crossinhibition induced by this whole protein [66,67].”
BackgroundDoritchamou, J. Y., Renn, J. P., Jenkins, B., Mahamar, A., Dicko, A., Fried, M., & Duffy, P. E. (2022) · eLife · doi:10.7554/elife.76264 · Cited by 23
Renn, J. P., Doritchamou, J. Y. A., Tentokam, B. C. N., Morrison, R. D., Cowles, M. V., Burkhardt, M., Ma, R., Mahamar, A., Attaher, O., Diarra, B. S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02787-7 · Cited by 24
Doritchamou, J., Teo, A., Morrison, R., Arora, G., Kwan, J., Manzella‐Lapeira, J., Medina, S., Langhorne, J., Hviid, L., Narum, D. L., et al. (2019) · Infection and Immunity · doi:10.1128/iai.00865-18 · Cited by 24
Doritchamou, J., Sabbagh, A., Jespersen, J. S., Renard, E., Salanti, A., Nielsen, M. A., Deloron, P., & Tuikue Ndam, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137695 · Cited by 22
Nunes-Silva, S., Dechavanne, S., Moussiliou, A., Pstrąg, N., Semblat, J., Gangnard, S., Ndam, N. T., Deloron, P., Chêne, A., & Gamain, B. (2015) · Malaria Journal · doi:10.1186/s12936-015-1008-5 · Cited by 22
“5 × 106 IEs were incubated with purified rabbit anti-IT4-VAR19 and purified antiVAR2CSA antibodies [28] diluted 1:100 in PBS 0.”
MethodSelf-citationDorin, D., Tétard, M., Claës, A., Semblat, J., Dechavanne, S., Fourati, Z., Hamelin, R., Armand, F., Matesic, G., Nunes-Silva, S., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000308 · Cited by 24
“The supernatant containing the solubilised native VAR2CSA was then incubated with a polyclonal rabbit antiVAR2CSA [56] coupled to magnetic protein G Dynabeads (Invitrogen France).”
MethodSelf-citationObiakor, H., Avril, M., MacDonald, N. J., Srinivasan, P., Reiter, K., Anderson, C., Holmes, K. L., Fried, M., Duffy, P. E., Smith, J. D., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00638-12 · Cited by 22
“Whereas full-length VAR2CSA recombinant proteins are highly immunogenic, the adhesion blocking activity they elicited was strain specific (19, 27).”
BackgroundSelf-citationProgress and new horizons toward a VAR2CSA-based placental malaria vaccine
Doritchamou, J., Suurbaar, J., & Ndam, N. T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1878029 · Cited by 21
“different animal models (mice, rat, and rabbits) with strong homologous, but limited heterologous blocking activities [67,85].”
BackgroundInfluentialKane, E. G., & Taylor-Robinson, A. W. (2011) · Malaria Research and Treatment · doi:10.4061/2011/764845 · Cited by 22
Bewley, M. C., Gautam, L., Jagadeeshaprasad, M. G., Gowda, D. C., & Flanagan, J. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014676 · Cited by 15
“By contrast, if DBL1x and DBL6e were adjacent, as suggested in the previous model for domain organization (62), then the putative CSA-binding domains (DBL1x-DBL2x) would be located nearer to the knob membrane, making it less accessible to the placental CSA chains.”
BackgroundVAR2CSA Signatures of High Plasmodium falciparum Parasitemia in the Placenta
Rovira-Vallbona, E., Monteiro, I. F., Bardají, A., Serra‐Casas, E., Neafsey, D. E., Quelhas, D., Valim, C., Alonso, P. L., Dobaño, C., Ordï, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069753 · Cited by 16
de Moraes, L. V., Dechavanne, S., Sousa, P. M., Barateiro, A., Cunha, S. F., Nunes-Silva, S., Lima, F. A., Murillo, O. J., Marinho, C. R. F., Gangnard, S., et al. (2016) · Infection and Immunity · doi:10.1128/iai.01207-15 · Cited by 13
“rabbit anti-DBL1-6 IgG (23) and TER 119-phycoerythrin (PE) (Molecu-”
BackgroundMethodInfluentialSelf-citationMa, R., Salinas, N. D., Orr-Gonzalez, S., Richardson, B., Ouahes, T., Torano, H., Jenkins, B. J., Dickey, T. H., Neal, J., Duan, J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011879 · Cited by 12
Saveria, T., Oleinikov, A. V., Wiliamson, K., Chaturvedi, R., Lograsso, J., Keitany, G. J., Fried, M., & Duffy, P. E. (2013) · Infection and Immunity · doi:10.1128/iai.00978-12 · Cited by 15
“When antibodies to the 3D7 full-length construct were tested for inhibition to heterologous lab isolates, no inhibition was observed (35), leaving open the question of whether or not a larger portion of VAR2CSA will enhance vaccine efficacy.”
MethodComparison of functional assays used in the clinical development of a placental malaria vaccine
Pehrson, C., Heno, K. K., Adams, Y., Resende, M., Mathiesen, L., Søgaard, M., de Jongh, W. A., Theander, T. G., Salanti, A., & Nielsen, M. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.12.028 · Cited by 13
Antigenic Variation, Adherence, and Virulence in Malaria
Smith, J. D., & Deitsch, K. (2012) · Wiley eBooks · doi:10.1002/9781118308165.ch18 · Cited by 6
Self-citationGuillotte-Blisnick, M., Juillerat, A., Igonet, S., Hessel, A., Pêtres, S., Crublet, E., Scanf, C. L., Lewit‐Bentley, A., Bentley, G. A., Vigan-Womas, I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134292 · Cited by 5
Using Population Genetics to Guide Malaria Vaccine Design
Alyssa, E., Beeson, J. G., John, C. F., Freya, J. I., & Arnott, A. (2012) · InTech eBooks · doi:10.5772/34031 · Cited by 5
Self-citationDevelopment of Pregnancy-Associated Malaria Vaccine Using the ExpreS2 Insect Cell Expression System
Dyring, C. (2012) · BioProcessing Journal · doi:10.12665/j113.dyring · Cited by 5
Talundzic, E., Scott, S., Owino, S. O., Campo, D. S., Lucchi, N. W., Udhayakumar, V., Moore, J. M., & Peterson, D. S. (2022) · Pathogens · doi:10.3390/pathogens11050520 · Cited by 4
“Indeed, early work found that human antibody recognition of VAR2CSA was strain-transcendent, leading to predictions of broad cross-protection by these responses [39,40].”
BackgroundRotich, A. K., Takashima, E., Yanow, S. K., Gitaka, J., & Kanoi, B. N. (2022) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2022.988284 · Cited by 5
“However, even antibodies to the full length VAR2CSA do not always inhibit binding of different placental cell lines to CSA (44).”
BackgroundLiu, P.-F., Wang, Y., Liu, Y., & Huang, C. (2017) · PubMed · Cited by 2
Mucke, H. A. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.18 · Cited by 1
Expanding the Toolbox in Pursuit of a Strain Transcendent Malaria Vaccine
Frosch, A. E. P., & John, C. C. (2014) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0662 · Cited by 1
Nunes-Silva, S., Dechavanne, S., Moussiliou, A., Pstrąg, N., Semblat, J., Gangnard, S., Ndam, N. T., Deloron, P., Chêne, A., & Gamain, B. (2016) · Malaria Journal · doi:10.1186/s12936-015-1061-0 · Cited by 1
Self-citationRovira-Vallbona, E. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Doritchamou, J. (2014) · theses.fr (ABES) · doi:10.70675/807a56b9z568cz4be9za174z2a9279384c68
Metadata
- Authors
- Avril, M., Hathaway, M. J., Srivastava, A., Dechavanne, S., Hommel, M., Beeson, J. G., Smith, J. D., & Gamain, B.
- Affiliations
- Center for Infectious Disease Research (US)
- Centre National de la Recherche Scientifique (FR)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Smith, Joseph D.
- Gamain, Benoît
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-07
- Volume
- 6
- Issue
- 2
- Pages
- e16622
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3034725
- OpenAlex
- W2023380419
- Cited by
- 40
- References
- 54
- Citations by year
- 2024: 1 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 3 · 2012: 7
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bill and Melinda Gates Foundation
- Sanofi
- European Commission (201222)
- Medical Research Council (FP7/20072013)
- Australian Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Life Sciences › Immunology and Microbiology › Parasitology › Vector-borne infectious diseases
- Keywords
- VAR2CSA, Plasmodium falciparum, placental adhesions, chondroitin sulfate A, Duffy binding-like domain, cross-reactive antibodies, adhesion inhibition, vaccine candidate
- MeSH terms
- Amino Acid Sequence, Animals, Antibodies, Protozoan, Antibody Specificity, Antigens, Protozoan, Cells, Cultured, Cross Reactions, Female, Humans, Immunization, Mice, Inbred BALB C, Placenta, Pregnancy, Rabbits, Species Specificity, Pregnancy Complications, Parasitic, Malaria, Falciparum, Malaria Vaccines, Protein Isoforms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.